Design World

  • Home
  • Technologies
    • 3D CAD
    • Electronics • electrical
    • Fastening & Joining
    • Factory automation
    • Linear Motion
    • Motion Control
    • Test & Measurement
    • Sensors
    • Fluid power
  • Learn
    • Ebooks / Tech Tips
    • Engineering Week
    • Future of Design Engineering
    • MC² Motion Control Classrooms
    • Podcasts
    • Videos
    • Webinars
  • LEAP AWARDS
  • Leadership
    • 2022 Voting
    • 2021 Winners
  • Design Guide Library
  • Resources
    • 3D Cad Models
      • PARTsolutions
      • TraceParts
    • Digital Issues
      • Design World
      • EE World
    • Women in Engineering
  • Supplier Listings

Theranos — and the satisfaction of how engineering doesn’t lie

By Lisa Eitel | April 23, 2019

Share

How does it work? That was the question few people asked about the mythical supertechnology supposedly at the core of Theranos — a Silicon-Valley unicorn overvalued by some $9 billion during a 2013-2014 hype height. Not that it would’ve mattered anyway, as the fictional heart of secretive Theranos changed continuously over its 12 short years.

As John Carreyrou of the Wall Street Journal details in his Bad Blood — a book delighting technical types — official engineering focus took multiple abrupt turnabouts … going from concept to commercialized product with scant R&D between.

Theranos final subsytems

Click to enlarge. Subsystems in the final Theranos design are common to motion design and medical diagnosis. A cartridge (7) allows initial loading of samples into the machine, and a camera (10) captures sample data for indexing processed results. A traditional Cartesian robot (1) moves samples around to subsystems in the machine. The sonicator (8) is a straightforward sample agitator. Other thermocycler (3), centrifuge (4), cytometer (5), thermal system (6), fluorescence-based isothermal detector (7), and spectrophotometer (11) offerings exist in industry; luminometer and fluorometer (9) biotechnologies have been around for decades. As Carreyrou details in Bad Blood, one company leader was so unfamiliar with the technologies inside the miniLab that its engineers were able to trick him into calling its sample-moving end effector an endofactor as a prank.

The company’s last offering — which one expert in laboratory medicine called “theater … not science” — includes technologies quite common to medical diagnosis and motion design. The staid components for the latter are quite familiar to the Design World and linearmotiontips.com audiences: Linear guides and dc motor-driven actuators form a small three-axis Cartesian setup for the movement of samples to various stations inside the testing cube. Check out the recent Motion Handbook’s section on stepper motors for a similar pipetting example …

Thomson Industries stepper-motor linear actuators include models with built-in anti-rotational guidance. The manufacturer’s motorized leadscrew actuator (MLA) saves designers of high-precision and shorter-stroke applications the cost, time, and maintenance worries related to designing and building externally guided systems themselves. Combining lead screws and stepper motors is a simple and common setup for precise linear motion.

But it was a long and winding road to the final Theranos design.

2005 — Theranos begins with the concept of skin-wearable blood diagnostics capable of drawing tiny amounts of blood through microneedles and responding with real-time drug therapy. Then it scales back its ambition to build a machine to execute batteries of tests on tiny volumes of blood using micro and nanotechnology. Ultimately, this takes the form of the erratic Theranos 1.0 — a machine that’s supposed to read data on blood-carrying cartridges using microfluidics and biochemistry.

2007 — Focus shifts away from the microfluidics to the humbler aim of traditional lab diagnostics — but still using drop-sized blood samples. The company modifies and reprograms Fisnar adhesive-dispensing machines to make the Edison. The unreliable machine only executes tests based on immunoassays and no other tests based on general chemistry, cytometry, and DNA amplification. But its look is sleek — created by former Apple designers.

2011 — Prompted by partnerships with Safeway and Walgreens, the company begins work on its miniLab (4s), an inconstant machine for executing multiple blood-test types. Variations on portable-analyzer and miniaturized-technology concepts Theranos is pursuing are in production by others, so the company is entering charted and crowded territory.

2013 — With the miniLab not ready for use in a Walgreens service rollout, Theranos secretly runs patient tests on its older sample-processing units and machines from other manufacturers — or sends them out to third-party laboratories. The company also resorts to running tests on patient blood samples (diluted to concentrations out of existing instruments’ sensitivity ranges) using hacked Siemens machines.

Ultimately it is a few engineers, scientists, and lab workers who triumph over deception, threats, intimidation, and triangulation to bring the fraud to light.

Of course, questions about the engineering as well as financials should have been asked sooner. Francine McKenna of marketwatch.com marvels at how investors duped out of some $700 million by the Theranos fraud failed to ask for audited financial information — a pretty standard request for verifying the monetary health and promise of a company. And British professor and experimental physicist Richard Jones adds at softmachines.org that innovation in the physical and biological realms is fundamentally more costly and difficult than that in the purely digital world — a fact for which realistic expectations on Thernos’ commercialization timeline should have accounted.

Jones also laments that the original Theranos patent (on the use of silicon microneedles from drawing blood and realtime treatment of detected conditions) was “astonishingly broad” — so roadblocks scientists who may have otherwise advanced related technologies for inexpensive yet reliable diagnostic testing.

But alas on this front at least, there is hope. Visit our sister sites massdevice.com and drugdeliverybusiness.com and search on point-of-care, wearable, and microfluidics for an abundance of news on promising research, devices, and technologies.

Many of the announcements detail successful trials that quantify results or demonstrate the functionality of technologies like the ones Theranos initially claimed to have in development. A company called Genalyte is developing a diagnostics device to accurate perform more than a dozen tests on just a few drops of blood. Abbott’s i-STAT handheld blood analyzer allows point-of-care testing with an ever-increasing array of test cartridges and connectivity options. J-Pac medical announces lab-on-chip reagent blister development kits for diagnostic applications. Nemaura shares data from home-use study of wearable glucose monitor. Raumedic shows solutions for wearable drug-injection devices at Pharmapack 2018 … and there’s lots more good news from the field.

In fact, one standout technology from DNA Medicine Institute has just become a subject of NASA’s Civilian Commercial Readiness Pilot Program (CCRPP) — granted to vetted designs demonstrating potential maturation aligning with NASA interests and eventual marketability. The program aims to give International Space Station astronauts point-of-patient care through rHEALTH small-volume blood analyzers and SKYE Sensor vitals monitors.

Only more peer reviews, research and development, testing, and regulatory clearances will prove rHEALTH or the other designs out. But it’s a delicious reality that the stubborn old fields of science and engineering ultimately demand verifiable results. ⚙️

This article originally appeared in the Design World Motion Handbook.

You may also like:


  • Motion control trends to learn about at Robotics Summit &…

  • Automate/ProMat 2019: 10 takeaways for robotics developers

  • Motion Trends: New motor breeds are smart, connected, and compact

  • Cannabis cultivation leverages modular automation stations

  • Motion Trends: Stages, Cartesian robots, and tables for complete motion…

Filed Under: ALL INDUSTRY NEWS • PROFILES • COMMENTARIES, Industry + job trends, TECHNOLOGIES + PRODUCTS, ALL INDUSTRIES, Medical, Drives (stepper) + amplifiers, Motors • stepper, Test + measurement • test equipment

 

About The Author

Lisa Eitel

Lisa Eitel has worked in the motion industry since 2001. Her areas of focus include motors, drives, motion control, power transmission, linear motion, and sensing and feedback technologies. She has a B.S. in Mechanical Engineering and is an inductee of Tau Beta Pi engineering honor society; a member of the Society of Women Engineers; and a judge for the FIRST Robotics Buckeye Regionals. Besides her motioncontroltips.com contributions, she also leads the production of the quarterly motion issues of Design World.

Related Articles Read More >

Renishaw and CCAT drive cutting-edge manufacturing and supply chain technologies
Increased innovation, digital presence increase igus online sales
Dorner-Virtual-Showcase
Dorner’s new Virtual Showcase now open with nine product demonstrations
mk North America announces new sales and business development manager

DESIGN GUIDE LIBRARY

“motion

Enews Sign Up

Motion Control Classroom

Design World Digital Edition

cover

Browse the most current issue of Design World and back issues in an easy to use high quality format. Clip, share and download with the leading design engineering magazine today.

EDABoard the Forum for Electronics

Top global problem solving EE forum covering Microcontrollers, DSP, Networking, Analog and Digital Design, RF, Power Electronics, PCB Routing and much more

EDABoard: Forum for electronics

Sponsored Content

  • Pushing performance: Adding functionality to terminal blocks
  • Get to Know Würth Industrial Division
  • Renishaw next-generation FORTiS™ enclosed linear encoders offer enhanced metrology and reliability for machine tools
  • WAGO’s smartDESIGNER Online Provides Seamless Progression for Projects
  • Epoxy Certified for UL 1203 Standard
  • The Importance of Industrial Cable Resistance to Chemicals and Oils

Design World Podcasts

June 12, 2022
How to avoid over engineering a part
See More >
Engineering Exchange

The Engineering Exchange is a global educational networking community for engineers.

Connect, share, and learn today »

Design World
  • Advertising
  • About us
  • Contact
  • Manage your Design World Subscription
  • Subscribe
  • Design World Digital Network
  • Engineering White Papers
  • LEAP AWARDS

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Design World

  • Home
  • Technologies
    • 3D CAD
    • Electronics • electrical
    • Fastening & Joining
    • Factory automation
    • Linear Motion
    • Motion Control
    • Test & Measurement
    • Sensors
    • Fluid power
  • Learn
    • Ebooks / Tech Tips
    • Engineering Week
    • Future of Design Engineering
    • MC² Motion Control Classrooms
    • Podcasts
    • Videos
    • Webinars
  • LEAP AWARDS
  • Leadership
    • 2022 Voting
    • 2021 Winners
  • Design Guide Library
  • Resources
    • 3D Cad Models
      • PARTsolutions
      • TraceParts
    • Digital Issues
      • Design World
      • EE World
    • Women in Engineering
  • Supplier Listings